If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBARK.L Regulatory News (BARK)

  • There is currently no data for BARK

CSS Announces Licensing Deal with Mammoth

19 Sep 2023 07:00

RNS Number : 8376M
Barkby Group PLC
19 September 2023
 

Barkby Group PLC

 

("Barkby" or the "Company")

 

 

Cambridge Sleep Sciences Announces Licensing Deal with Mammoth

 

 

Barkby (AIM: BARK) announces that its subsidiary, Cambridge Sleep Sciences, ("CSS") the science-based sleep technology business behind SleepEngine®, has granted a five-year global license, (the "Agreement") to Mammoth International Ltd., ("MIL") enabling it to manufacture a Smart Mattress using CSS's SleepEngine® platform.

 

Under the terms of the Agreement, MIL will incorporate CSS's sleep technology into a new Smart Mattress product line it has developed. For each CSS-enabled mattress MIL produces, it will pay CSS a royalty of £75 per single mattress and £150 per double mattress.

 

MIL's Smart Mattress product line will be launched at the end of September with manufacturing commencing within the next six months. It expects to produce approximately 5,000 mattresses in the year following launch.

 

Dr Julian Stone, CEO of CSS, said: 

"We're delighted to be working with Mammoth, helping it to enhance its product range with a new Smart Mattress. Mammoth has strong credentials, particularly in specialist health and sport mattresses and our technology is a natural extension of their design ethos."

 

SleepEngine® technology has been developed and refined over more than a decade by a team of researchers, scientists, sound and medical experts. The result is a unique audio solution that helps to retrain the brain to restore healthy natural sleep patterns, a key component for mental, physical, and cognitive wellbeing. SleepEngine® technology offers a unique integration opportunity with existing or new third-party products capable of delivering high quality audio.

 

Mammoth International Ltd is a new UK based subsidiary of the Mammoth Comfort Group set up to take advantage of new technologies at the medical end of mattress design.

 

CSS remains in advanced negotiations with several household names on a number of new multi-year enterprise licensing deals for its SleepEngine® technology. Further announcements will be made as soon as practicable when these licences are signed.

 

- Ends -

 

For more information

 

Barkby Group plc

Charles Dickson, Executive Chairman

 

c/o Montfort

Cavendish Capital Markets Limited (Nomad and Broker)

Carl Holmes and Simon Hicks (Corporate Finance)

Tim Redfern (ECM)

 

+44 (0)20 7220 0500

Montfort

Olly Scott

Georgia Colkin

 

+44 (0)78 1234 5205

 

 

About Barkby

Barkby is a roadside real estate business focused on building and scaling a high-quality portfolio of modern, ESG-compliant assets. It is in the process of exiting its non-core investments.

 

 

About Cambridge Sleep Sciences Ltd

Cambridge Sleep Sciences Ltd, part of the Life Sciences division of The Barkby Group Plc, develops technology which improves natural sleep. Using the principles of neuroscience and cutting-edge technology to enhance brain activity during sleep, its innovative solutions aim to improve health, wellbeing and enhance quality of life. 

 

Its SleepEngine® technology has been developed and refined over a decade by a team of researchers, scientists, sound engineers and medical experts. This unique technology produces sounds which emulate the waves created by the brain during sleep cycles. The sleep sounds guide the user's brain through the sequence of healthy sleep cycles, helping them fall asleep and achieve the quality of sleep they need in a consistent and optimal way.

 

Find out more at: www.cambridgesleepsciences.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFUFZGMLGRZGFZZ
12
Date   Source Headline
30th Jan 20246:03 pmRNSChange of Name to Roadside Real Estate plc
2nd Jan 20247:00 amRNSResult of General Meeting
19th Dec 202311:15 amRNSUpdate on debt refinancing and CSS
15th Dec 20237:00 amRNSFirst joint venture acquisition
13th Dec 20235:39 pmRNSPosting of Circular and Notice of General Meeting
4th Dec 20237:00 amRNSIntention to refinance debt facilities
7th Nov 20237:00 amRNSPractical completion of second Roadside asset
31st Oct 20237:00 amRNSFormation of Roadside Real Estate Joint Venture
29th Sep 20237:00 amRNSTrading update
19th Sep 20237:00 amRNSCSS Announces Licensing Deal with Mammoth
11th Sep 20237:00 amRNSResponse to media speculation re CSS
1st Aug 20237:00 amRNSDisposal of Workshop Coffee
14th Jun 20237:42 amRNSCSS announces new licensing agreement
9th Jun 20237:00 amRNSPub portfolio update
6th Jun 20237:00 amRNSMajor licensing deal for Cambridge Sleep Sciences
31st May 20237:00 amRNSPractical completion of first Roadside asset
15th May 20237:00 amRNSBoard Update, Equity Issue & Total Voting Rights
31st Mar 20237:00 amRNSInterim results
22nd Feb 20235:26 pmRNSResult of AGM
16th Jan 20237:00 amRNSNotice of AGM & Debt Facility Drawing
30th Dec 20227:01 amRNSFinal results for the year ended 2 July 2022
30th Dec 20227:00 amRNSRevised debt facility
28th Nov 20227:00 amRNSTrading and Strategy Update
25th Nov 20227:00 amRNSAcquisition of the Eliot Arms
7th Sep 20225:48 pmRNSHolding(s) in Company
18th Jul 20227:00 amRNSTrading and Strategy Update
21st Jun 20223:19 pmRNSDirector/PDMR Shareholding
11th May 20225:21 pmRNSHolding(s) in Company
26th Apr 20227:00 amRNSExchange of Contracts at Saffron Walden, Essex
1st Apr 20227:00 amRNSAcquisition of The Coach and Horses
30th Mar 20227:20 amRNSInterim Results
4th Mar 20226:09 pmRNSHolding(s) in Company
3rd Mar 20227:00 amRNSAppointment of Group Property Director
2nd Mar 20227:00 amRNSVerso Biosense completes clinical study
1st Mar 20227:00 amRNSBoard Update
8th Feb 20225:35 pmRNSResult of AGM
3rd Feb 20223:33 pmRNSIssue of Equity and Total Voting Rights
25th Jan 20227:00 amRNSCambridge Sleep Sciences Announces New Partners
18th Jan 20227:00 amRNSVerso Biosense study nears completion
13th Jan 20227:00 amRNSPosting of Annual Report & Notice of AGM
24th Dec 20217:00 amRNSFinal Results for the Year Ended 1 July 2021
20th Dec 20212:06 pmRNSSecond Price Monitoring Extn
20th Dec 20212:00 pmRNSPrice Monitoring Extension
17th Dec 20217:00 amRNSExchange of Contracts in Swindon, Wiltshire
27th Oct 20214:41 pmRNSSecond Price Monitoring Extn
27th Oct 20214:35 pmRNSPrice Monitoring Extension
27th Oct 20212:05 pmRNSSecond Price Monitoring Extn
27th Oct 20212:00 pmRNSPrice Monitoring Extension
27th Oct 202111:05 amRNSSecond Price Monitoring Extn
27th Oct 202111:00 amRNSPrice Monitoring Extension
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.